Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine

Hans Rasmussen*, Bjorn H. Ebdrup, David Erritzoe, Bodil Aggernaes, Bob Oranje, Jan Kalbitzer, Lars H. Pinborg, William F C Baaré, Claus Svarer, Henrik Lublin, Gitte M. Knudsen, Birte Glenthoj

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Scopus)

Abstract

Rationale: We have previously reported decreased frontal cortical serotonin2A receptor binding in 30 antipsychotic naïve first-episode schizophrenic patients and a relationship between this binding and positive psychotic symptoms. Until now, no longitudinal studies of serotonin2A receptor in first-episode antipsychotic-naïve schizophrenia patients have reported on the relationship between serotonin2A receptor occupancy and treatment effect after sustained treatment with a specific atypical antipsychotic compound. Objectives: Here, we measured serotonin2A receptor occupancy with [ 18F]altanserin PET in 15 first-episode antipsychotic-naïve schizophrenia patients before and after 6 months of quetiapine treatment. Moreover, we investigated possible relationships between clinical efficacy, oral dose, and plasma levels of quetiapine Results: Significant nonlinear relationships were found between serotonin2A receptor occupancy, quetiapine dose, and plasma concentration. There was a modest effect on positive symptoms up until a serotonin2A receptor occupancy level of approximately 60%. A receptor occupancy level between 60% and 70% appeared to exert the optimal serotonin2A receptor related treatment effect on positive symptoms whereas no additional serotonin2A receptor associated treatment effect was obtained above a receptor occupancy of 70%. Conclusions: Taken together, the data point to a therapeutic role of the serotonin2A receptor in the treatment of subgroups of patients with schizophrenia. Specifically, the study indicates a serotonin2A receptor associated therapeutic window on positive symptoms in responding patients in the range between 60% and 70% occupancy in antipsychotic-naïve first-episode schizophrenia. We speculate that non-responding patients need higher dopamine D2 receptor blockade. Future studies with concurrent measurement of interactions with the dopamine system are, however, warranted to clarify this.

Original languageEnglish
Pages (from-to)583-592
Number of pages10
JournalPsychopharmacology
Volume213
Issue number2-3
DOIs
Publication statusPublished - 1 Feb 2011

Keywords

  • First-episode
  • PET. 5-HT
  • Quetiapine
  • Receptor occupancy
  • Schizophrenia

Fingerprint

Dive into the research topics of 'Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine'. Together they form a unique fingerprint.

Cite this